查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010013

体外诊断市场：2026年至2032年全球市场预测，依产品、检测类型、检体类型、应用、最终用户和患者群体划分

In-Vitro Diagnostics Market by Offering, Test Type, Specimen, Application, End User, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，体外诊断市场价值将达到 1,099.9 亿美元，到 2026 年将成长至 1,173.1 亿美元，到 2032 年将达到 1,751.4 亿美元，复合年增长率为 6.87%。

主要市场统计数据
基准年 2025 1099.9亿美元
预计年份：2026年 1173.1亿美元
预测年份 2032 1751.4亿美元
复合年增长率 (%) 6.87%

为现代体外诊断市场的领导者提供策略展望，以技术融合、临床需求和营运重点为框架。

体外诊断处于临床需求、技术创新和医疗保健系统经济的交汇点，需要清晰且可操作的见解，才能帮助相关人员驾驭这一快速发展的领域。本报告首先将诊断置于现代临床工作流程中，重点在于阐述仪器、检测设计和数位分析的进展如何重塑诊断流程。随后，报告追踪了这些进步在检查室、医院和即时检验 (POC) 环境中的实际影响，揭示了营运压力和监管预期如何影响引进週期和投资决策。

自动化、数位分析、即时护理的扩展以及不断变化的法规如何全面重塑诊断开发、交付和营运策略。

在诊断领域，一系列变革正在发生，它们正在重新定义整个医疗保健系统中诊断方法的开发、检验和实施方式。自动化和定序技术的进步提高了处理能力，并扩展了可进行的检测范围。同时，诊断软体与云端原生分析的融合，正在将原始数据转化为可操作的临床见解。因此，决策者们不得不权衡传统的资本密集型检查室投资与强调敏捷性和持续改进的新型「软体优先」模式。

关税趋势的变化迫使诊断服务提供者和买家重新设计其采购、物流和商业化策略，以维持供应的连续性和价格竞争力。

2025年美国关税环境对整个诊断供应链、采购定价和筹资策略都带来了巨大压力，迫使相关人员重新评估与供应商的关係以及对零件的依赖程度。进口试剂、耗材和某些仪器组件的关税导致成本增加，促使各方更加重视供应链透明度和多元化采购策略。采购团队加快了二级供应商的认证速度，供应商也调整了经营模式，透过本地生产、重新谈判合约条款或重新设计产品来应对不断上涨的接收成本，从而减少对受关税影响的原材料的依赖。

透过进行综合細項分析，识别产品类型、测试方法、检体考量、临床应用和最终用户趋势的交集，可以创造策略机会。

基于产品、测试、检体、应用和最终用户等关键细分框架进行分析，能够最清楚地洞察需求驱动因素和市场采纳模式。市场趋势的研究涵盖了仪器、试剂/试剂盒和软体/服务等产品类型。仪器进一步细分为分析仪器、自动化系统和定序仪，而软体/服务则分为校准服务、咨询服务、诊断软体和维护服务。这种观点揭示了资本设备生命週期、耗材依赖和业务收益如何相互作用，从而影响供应商策略和客户采购偏好。

世界各地不同的管理体制、医疗基础设施和采购实务如何影响诊断技术的应用模式和商业策略？

区域趋势对全球各大区域的竞争策略和部署重点产生了不同的影响。在美洲，成熟的检查室网路、大规模私人保险公司以及对以价值为导向的医疗保健模式的高度重视（这种模式重视诊断准确性和更快的回应速度）共同推动了市场需求。因此，在该地区运营的供应商通常优先考虑高通量仪器、全面的试剂组合以及与集中式实验室资讯系统的兼容性，以满足大规模医院网路和参考实验室的需求。

在临床环境中，竞争差异化越来越依赖整合的产品生态系统、策略伙伴关係和服务主导的经营模式，以确保信任和永续的收入。

在这个领域，竞争优势越来越取决于企业能否将卓越的技术、服务能力和策略伙伴关係融会贯通。主要企业透过整合高效能仪器、专有试剂和强大的软体生态系统，打造整合解决方案，从而实现数据驱动的洞察，以此脱颖而出。其他企业则专注于细分领域，提供一流的诊断方法和专为即时检测环境优化的紧凑型平台，同时利用临床伙伴关係关係来检验产品性能并加速其在临床环境中的部署。

要将技术创新转化为永续的商业性优势，我们需要采取切实可行的策略行动，协调平台设计、监管合规、供应链弹性和服务扩展。

产业领导企业应采取一系列协调一致的措施，将研发、监管策略和商业性执行结合，以建立长期韧性，同时满足短期临床需求。首先，优先建构模组化平台架构，该架构既支援集中式高通量分析，也支援分散式即时检测部署，从而灵活服务于不同的客户群。其次，尤其对于软体主导的诊断产品，应从产品开发的早期阶段就投资于监管准备工作，以缩短认证时间并最大限度地降低跨辖区适应成本。第三，透过供应商多元化、区域製造伙伴关係和策略性库存管理来增强供应链韧性，从而抵御关税和物流波动的影响。

为了确保获得可靠且可操作的见解，我们采用了严格的混合方法研究途径，结合了与关键相关人员的访谈、技术检验和基于场景的压力测试。

为确保可靠性和有效性，本分析所依据的研究采用了多层次的调查方法，整合了访谈、技术文件审查和结构化检验。访谈包括对实验室经理、采购经理、临床专家以及仪器和试剂供应商的高阶主管进行详细访谈，以了解目前的决策标准、营运限制和策略重点。此外，还对监管指南、临床文献和产品技术规范进行了系统性审查，以检验性能声明并梳理监管路径，从而补充了上述定性资讯。

综合策略结论强调了协调技术创新、临床证据和营运韧性的重要性，以确保长期部署和商业性成功。

如果产业相关人员能够将技术创新与切实可行的商业和营运策略相结合，体外诊断仍将是改善病患预后和优化诊疗路径的重要策略工具。本报告的综合分析表明，那些将平台柔软性、可靠的检验证据和稳健的供应链模式融入其价值提案的组织才能取得成功。同样重要的是，企业还需具备将技术差异化转化为服务模式的能力，从而深化客户关係并提供可预测的收入来源。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 体外诊断市场：依产品/服务分类

  • 装置
    • 分析器
    • 自动化系统
    • 定序装置
  • 试剂和试剂盒
  • 服务
    • 安装和验证服务
    • 培训和咨询服务
    • 维护和支援服务
  • 软体和资讯系统
    • 检查室资讯系统
    • 数据分析与解释软体

第九章 体外诊断市场（依检测类型划分）

  • 临床化学
    • 血液分析
    • 电解质面板
    • 肝功能检查
    • 甲状腺功能检查
    • 尿液检查
  • 血液学
  • 免疫检测
  • 微生物学
  • 分子诊断

第十章检体类型分類的体外诊断试剂市场

  • 血液、血清和血浆
  • 唾液
  • 组织样本
  • 尿

第十一章 体外诊断市场：依应用划分

  • 自体免疫疾病
  • 癌症筛检
  • 心臟监测
  • 糖尿病管理
  • 基因检测
  • 传染病检查

第十二章 体外诊断市场：依最终用户划分

  • 学术和研究机构
  • 诊断检查室
  • 医院
  • 即时检测中心

第十三章 依病患类型分類的体外诊断市场

  • 成人
  • 儿童

第十四章 体外诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 体外诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 体外诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国体外诊断市场

第十八章：中国体外诊断市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agappe Diagnostics Ltd.
  • Agilent Technologies, Inc.
  • ARKRAY Inc.
  • Asahi Kasei Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Edan Instruments, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • HiMedia Laboratories Pvt. Ltd.
  • Hitachi High-Tech Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • J Mitra & Co. Pvt. Ltd.
  • KAINOS Laboratories, Inc.
  • Kyowa Medex Co., Ltd.
  • Meril Diagnostics Pvt. Ltd.
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Revvity, Inc.
  • Seegene, Inc.
  • Sekisui Medical Co., Ltd.
  • Shanghai Kehua Bio-engineering Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • Sino Biopharmaceutical Limited
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Transasia Bio-Medicals Ltd.
  • Werfen, SA
  • Zhejiang Orient Gene Biotech Co.,Ltd.
Product Code: MRR-434CCDA04D33

The In-Vitro Diagnostics Market was valued at USD 109.99 billion in 2025 and is projected to grow to USD 117.31 billion in 2026, with a CAGR of 6.87%, reaching USD 175.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 109.99 billion
Estimated Year [2026] USD 117.31 billion
Forecast Year [2032] USD 175.14 billion
CAGR (%) 6.87%

A strategic orientation to the contemporary in-vitro diagnostics environment that frames technological convergence, clinical imperatives, and operational priorities for leaders

In-vitro diagnostics sit at the intersection of clinical need, technological innovation, and health-system economics, and stakeholders require clear, actionable intelligence to navigate this rapidly evolving field. The report opens by situating diagnostics within contemporary clinical workflows, highlighting how advances in instrumentation, assay design, and digital analytics are reshaping diagnostic pathways. It then traces the practical implications for laboratories, hospitals, and point-of-care settings, acknowledging how operational pressures and regulatory expectations influence adoption cycles and investment decisions.

Moving from context to consequence, the introduction frames the core vectors of change-technology convergence, shifting care delivery models, and supply chain recalibration-and explains why these vectors matter to executive teams, clinical leaders, and technology vendors. It emphasizes the need for strategies that balance clinical performance with cost-efficiency and regulatory compliance, while also preserving the agility to adapt to emergent public health demands. The narrative closes by outlining the structure of the analysis that follows, clarifying how subsequent sections translate complex dynamics into prioritized insights and practical recommendations for stakeholders seeking competitive and clinical advantage.

How automation, digital analytics, point-of-care expansion, and regulatory evolution are collectively reshaping diagnostic development, delivery, and operational strategy

The diagnostics landscape is experiencing a series of transformative shifts that are redefining how diagnostics are developed, validated, and deployed across care settings. Advances in automation and sequencing technologies are enabling higher throughput and broader test menus, while the integration of diagnostic software and cloud-native analytics is turning raw assay outputs into actionable clinical intelligence. As a result, decision-makers must reconcile traditional capital-intensive laboratory investments with emerging software-first models that emphasize agility and continuous improvement.

Concurrently, point-of-care testing is moving beyond rapid antigen models to embrace more sophisticated analyzers and compact molecular platforms, shifting diagnostic capacity closer to patients and accelerating clinical decision timelines. Regulatory frameworks are also evolving to address software as a medical device and to streamline pathways for companion diagnostics, creating both opportunities and compliance complexities. Moreover, supply chain resilience and the reshoring of critical components are now strategic priorities, informing procurement criteria and partnership strategies. Taken together, these shifts are prompting a re-evaluation of product road maps, commercialization strategies, and clinical validation approaches, and they demand integrated responses that align commercial, clinical, and operational objectives.

Evolving tariff dynamics have forced diagnostic providers and buyers to redesign sourcing, logistics, and commercialization strategies to preserve supply continuity and competitive pricing

The U.S. tariff environment in 2025 introduced substantive pressures across diagnostic supply chains, procurement pricing, and sourcing strategies, compelling stakeholders to reassess vendor relationships and component dependencies. Tariff-driven cost increases for imported reagents, consumables, and select instrumentation components have translated into sharper prioritization of supply chain transparency and multi-sourcing strategies. Procurement teams have accelerated qualification of secondary suppliers, and vendors have adjusted commercial models to accommodate increased landed costs through localized manufacturing, renegotiated terms, or product redesign that lowers exposure to tariffed inputs.

In parallel, regulatory and customs compliance burdens have grown, prompting greater emphasis on documentation, classification accuracy, and cross-border logistics planning. Clinical laboratories and distributors have responded by enhancing inventory management and by negotiating longer-term contracts that provide price predictability and supply continuity. Importantly, the tariff landscape has stimulated strategic investment in regional manufacturing hubs and collaborative alliances aimed at reducing reliance on single-country sourcing. Consequently, tariff dynamics are no longer a short-term procurement complication but an enduring factor shaping capital allocation, pricing strategies, and partnership models across the diagnostics value chain.

Integrated segmentation analysis revealing where product types, test modalities, specimen considerations, clinical applications, and end-user dynamics intersect to create strategic opportunities

Insight into demand drivers and adoption patterns emerges most clearly when analysis is structured around the primary segmentation frameworks used by product, test, specimen, application, and end-user categories. Based on product type, the landscape is studied across Instruments, Reagents & Kits, and Software & Services, with Instruments further analyzed through Analyzers, Automation Systems, and Sequencing Instruments, and Software & Services further divided into Calibration Services, Consultancy Services, Diagnostic Software, and Maintenance Services. This lens reveals how capital equipment lifecycles, consumable dependencies, and service revenues interact to shape vendor strategies and client procurement preferences.

Based on test type, the study examines Clinical Chemistry, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics, with Clinical Chemistry further detailed across Blood Analysis, Electrolyte Panel, Liver Panel, Thyroid Function Panel, and Urine Analysis. This taxonomy highlights where clinical demand is concentrated and where innovation-such as multiplex assays or digital interpretation-creates differentiation. Based on specimen, the analysis covers Blood, Serum & Plasma, Saliva, Tissue Samples, and Urine, indicating how specimen type influences sample handling workflows and pre-analytical requirements. Based on application, the study considers Autoimmune Diseases, Cancer Detection, Cardiac Monitoring, Diabetes Management, Genetic Testing, and Infectious Disease Testing to clarify clinical use cases that drive adoption. Finally, based on end user, the work assesses Academic & Research Centers, Diagnostic Laboratories, Hospitals, and Point-Of-Care Testing Centers to illuminate procurement cycles, reimbursement sensitivities, and operational readiness. By integrating these segmentation dimensions, the analysis surfaces which product-test-specimen-application-end user combinations present the clearest pathways for product differentiation, clinical validation prioritization, and tailored go-to-market execution.

How differing regulatory regimes, healthcare infrastructures, and procurement behaviors across global regions are influencing diagnostic adoption patterns and commercial strategies

Regional dynamics are shaping competitive strategies and deployment priorities in distinctly different ways across the world's major geographies. In the Americas, demand is driven by a combination of mature laboratory networks, large private payers, and a strong emphasis on value-based care models that reward diagnostic accuracy and time-to-result improvements. Consequently, suppliers operating in this region often emphasize high-throughput instruments, comprehensive reagent portfolios, and compatibility with centralized laboratory information systems to meet the needs of large hospital networks and reference laboratories.

In Europe, Middle East & Africa, regulatory harmonization initiatives and heterogeneous reimbursement environments produce a fragmented adoption landscape. Manufacturers and distributors must navigate diverse national regulatory requirements while adapting pricing and service models to varied procurement practices. Strategic partnerships and localized service capabilities are therefore critical to achieving traction. In Asia-Pacific, rapid expansion of diagnostic capacity, significant public health investment, and the proliferation of private healthcare providers are driving demand for scalable automation, molecular testing platforms, and decentralized testing solutions. Across these regions, differences in supply chain maturity, regulatory timelines, and clinical priorities inform how vendors sequence market entry, allocate resources for clinical validation, and structure commercial partnerships.

Competitive differentiation increasingly depends on integrated product ecosystems, strategic partnerships, and service-led business models that secure clinical trust and recurring revenue

Competitive positioning in this sector is increasingly determined by a company's ability to combine technical excellence with service capabilities and strategic partnerships. Leading firms differentiate through integrated solutions that couple high-performance instruments with proprietary reagents and robust software ecosystems that enable data-driven insights. Other players focus on niche specialization, providing best-in-class assays or compact platforms tailored for point-of-care environments, and they leverage clinical partnerships to validate performance and accelerate clinical adoption.

Partnership strategies are also central to growth, with collaborations spanning co-development, distribution alliances, and service networks that expand geographic reach. Meanwhile, aftermarket services such as calibration, maintenance, and consultancy not only create recurring revenue streams but also deepen customer relationships and reduce churn. New entrants tend to compete on speed of innovation and focused clinical use cases, while incumbent vendors emphasize scale, regulatory experience, and established relationships with health systems. Taken together, these dynamics underscore the importance of aligning product road maps, commercial models, and service delivery to capture clinical trust and long-term contracts.

Practical strategic actions to align platform design, regulatory preparedness, supply resilience, and service expansion to convert technical innovation into enduring commercial advantage

Industry leaders should adopt a coordinated set of actions that align R&D, regulatory strategy, and commercial execution to capture near-term clinical needs while building long-term resilience. First, prioritize modular platform architectures that support both centralized high-throughput analytics and decentralized point-of-care deployments, enabling flexible responses to diverse customer segments. Second, invest in regulatory-readiness early in product development, particularly for software-driven diagnostics, to reduce time-to-qualification and to minimize adaptation costs across jurisdictions. Third, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and strategic inventory management to buffer against tariff and logistics volatility.

Furthermore, expand service portfolios to include calibration, maintenance, and consultancy offerings that embed products within customer workflows and create recurring revenue. Leverage real-world performance data to build clinical and economic evidence packages that support reimbursement discussions and drive clinician confidence. Finally, pursue selective partnerships with clinical networks and academic centers to accelerate validation and to demonstrate clinical utility in high-impact applications. These combined actions will help organizations convert technical capability into enduring commercial advantage while mitigating regulatory and supply-side risks.

A rigorous mixed-methods research approach combining primary stakeholder interviews, technical validation, and scenario stress-testing to ensure credible and actionable insights

The research underpinning this analysis employed a layered methodology that integrates primary interviews, technical document review, and structured triangulation to ensure robustness and relevance. Primary research included in-depth interviews with laboratory directors, procurement leads, clinical specialists, and senior executives from equipment and reagent suppliers to capture current decision criteria, operational constraints, and strategic priorities. These qualitative inputs were complemented by systematic review of regulatory guidance, clinical literature, and product technical specifications to validate performance claims and to map regulatory pathways.

Quantitative validation was achieved through cross-referencing procurement patterns, device filings, and published clinical evaluation studies, enabling a consolidated view of adoption drivers and technical trade-offs. Throughout the process, findings were stress-tested through advisor reviews and scenario analysis to identify sensitivities and to surface practical mitigation approaches. Data governance practices ensured traceability and confidentiality of primary inputs, and methodological limitations were identified explicitly to contextualize interpretation. This rigorous, mixed-methods approach supports credible, actionable insights that are directly relevant to commercial planning and clinical strategy.

Consolidated strategic conclusions emphasizing the imperative to align technological innovation, clinical evidence, and operational resilience to secure long-term adoption and commercial success

In-vitro diagnostics are poised to remain a strategic lever for improving patient outcomes and for optimizing care pathways, provided that industry actors align technological innovation with pragmatic commercial and operational strategies. The synthesis presented here emphasizes that success will come to those organizations that integrate platform flexibility, robust validation evidence, and resilient supply chain models into their value propositions. Equally important is the ability to translate technical differentiation into service models that deepen customer relationships and provide predictable revenue streams.

Looking ahead, leaders must remain vigilant to regulatory evolution, to shifting care delivery patterns that favor decentralization, and to macroeconomic forces that affect sourcing and pricing. By prioritizing interoperability, evidence generation, and regional adaptability, stakeholders can convert complexity into competitive advantage. Ultimately, the capacity to synthesize clinical relevance with operational feasibility will determine which technologies achieve lasting clinical adoption and commercial traction.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Market, by Offering

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Automation Systems
    • 8.1.3. Sequencing Instrument
  • 8.2. Reagents & Kits
  • 8.3. Services
    • 8.3.1. Installation & Validation Services
    • 8.3.2. Training & Consulting Services
    • 8.3.3. Maintenance & Support Services
  • 8.4. Software & Informatics
    • 8.4.1. Laboratory Information Systems
    • 8.4.2. Data Analytics & Interpretation Software

9. In-Vitro Diagnostics Market, by Test Type

  • 9.1. Clinical Chemistry
    • 9.1.1. Blood Analysis
    • 9.1.2. Electrolyte Panel
    • 9.1.3. Liver Panel
    • 9.1.4. Thyroid Function Panel
    • 9.1.5. Urine Analysis
  • 9.2. Hematology
  • 9.3. Immunoassays
  • 9.4. Microbiology
  • 9.5. Molecular Diagnostics

10. In-Vitro Diagnostics Market, by Specimen

  • 10.1. Blood, Serum & Plasma
  • 10.2. Saliva
  • 10.3. Tissue Samples
  • 10.4. Urine

11. In-Vitro Diagnostics Market, by Application

  • 11.1. Autoimmune Diseases
  • 11.2. Cancer Detection
  • 11.3. Cardiac Monitoring
  • 11.4. Diabetes Management
  • 11.5. Genetic Testing
  • 11.6. Infectious Disease Testing

12. In-Vitro Diagnostics Market, by End User

  • 12.1. Academic & Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Point-Of-Care Testing Centers

13. In-Vitro Diagnostics Market, by Patient Type

  • 13.1. Adults
  • 13.2. Pediatrics

14. In-Vitro Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In-Vitro Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In-Vitro Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States In-Vitro Diagnostics Market

18. China In-Vitro Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agappe Diagnostics Ltd.
  • 19.7. Agilent Technologies, Inc.
  • 19.8. ARKRAY Inc.
  • 19.9. Asahi Kasei Corporation
  • 19.10. Becton, Dickinson and Company
  • 19.11. Bio-Rad Laboratories, Inc.
  • 19.12. bioMerieux SA
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin S.p.A.
  • 19.15. Edan Instruments, Inc.
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Grifols S.A.
  • 19.18. HiMedia Laboratories Pvt. Ltd.
  • 19.19. Hitachi High-Tech Corporation
  • 19.20. Hologic, Inc.
  • 19.21. Illumina, Inc.
  • 19.22. J Mitra & Co. Pvt. Ltd.
  • 19.23. KAINOS Laboratories, Inc.
  • 19.24. Kyowa Medex Co., Ltd.
  • 19.25. Meril Diagnostics Pvt. Ltd.
  • 19.26. Nihon Kohden Corporation
  • 19.27. PerkinElmer, Inc.
  • 19.28. QIAGEN N.V.
  • 19.29. QuidelOrtho Corporation
  • 19.30. Revvity, Inc.
  • 19.31. Seegene, Inc.
  • 19.32. Sekisui Medical Co., Ltd.
  • 19.33. Shanghai Kehua Bio-engineering Co., Ltd.
  • 19.34. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 19.35. Siemens AG
  • 19.36. Sino Biopharmaceutical Limited
  • 19.37. Sysmex Corporation
  • 19.38. Thermo Fisher Scientific, Inc.
  • 19.39. Tosoh Corporation
  • 19.40. Transasia Bio-Medicals Ltd.
  • 19.41. Werfen, S.A.
  • 19.42. Zhejiang Orient Gene Biotech Co.,Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTALLATION & VALIDATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTALLATION & VALIDATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTALLATION & VALIDATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA ANALYTICS & INTERPRETATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA ANALYTICS & INTERPRETATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA ANALYTICS & INTERPRETATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 229. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 235. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 262. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 268. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 273. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 279. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)